Cardio-facio-cutaneous Syndrome with Severe Inflammatory Cutaneous Lesions: Dramatic Effect of Dupilumab
DOI:
https://doi.org/10.2340/actadv.v104.40465Keywords:
Dupilumab, ichthyosis, IgE, allergy, atopic dermatitis, cardiofaciocutaneous syndrome, CFCAbstract
Abstract is missing (Short communication)
Downloads
References
Sereme Y, Casanovas N, Michel M, Martin-Blondel A, Mankouri F, Pinchemel S, et al. IgG removal significantly enhances detection of microarray allergen-specific IgE reactivity in patients' serum. Allergy 2021; 76: 395-398.
https://doi.org/10.1111/all.14536 DOI: https://doi.org/10.1111/all.14536
Wang J, Yu L, Zhang S, Wang C, Li Z, Li M, et al. Successful treatment of Netherton syndrome with dupilumab: a case report and review of the literature. J Dermatol 2022; 49: 165-167.
https://doi.org/10.1111/1346-8138.16253 DOI: https://doi.org/10.1111/1346-8138.16253
Inaba Y, Kanazawa N, Muraoka K, Yariyama A, Kawaguchi A, Kunimoto K, et al. Dupilumab improves pruritus in Netherton syndrome: a case study. Children 2022; 9: 310.
https://doi.org/10.3390/children9030310 DOI: https://doi.org/10.3390/children9030310
Tehrany YA, Marois L, Colmant C, Marchand V, Kokta V, Coulombe J, et al. Refractory pruritus responds to dupilumab in a patient with TTC7A mutation. JAAD Case Reports 2021; 8: 9-12.
https://doi.org/10.1016/j.jdcr.2020.12.004 DOI: https://doi.org/10.1016/j.jdcr.2020.12.004
Ollech A, Mashiah J, Lev A, Simon AJ, Somech R, Adam E, et al. Treatment options for DOCK8 deficiency-related severe dermatitis. J Dermatol 2021; 48: 1386-1393.
https://doi.org/10.1111/1346-8138.15955 DOI: https://doi.org/10.1111/1346-8138.15955
Alzahrani N, Grossman-Kranseler J, Swali R, Fiumara K, Zancanaro P, et al. Hailey-Hailey disease treated with dupilumab: a case series. Br J Dermatol 2021; 185: 680-682.
https://doi.org/10.1111/bjd.20475 DOI: https://doi.org/10.1111/bjd.20475
Butler DC, Kollhoff A, Berger T. Treatment of Grover disease with dupilumab. JAMA Dermatol. 2021; 157: 353-356. 35.
https://doi.org/10.1001/jamadermatol.2020.5097 DOI: https://doi.org/10.1001/jamadermatol.2020.5097
Seth S, Biswas T, Biswas B, Roy A, Datta AK. Cardiofaciocutaneous syndrome: case report of a rare disorder. J Clin Diagn Res 2016; 10: SD01-SD02.
https://doi.org/10.7860/JCDR/2016/21586.8811 DOI: https://doi.org/10.7860/JCDR/2016/21586.8811
Weiss G, Confino Y, Shemer A, Trau H. Cutaneous manifestations in the cardiofaciocutaneous syndrome, a variant of the classical Noonan syndrome: report of a case and review of the literature. J Eur Acad Dermatol Venereol 2004; 18: 324-327.
https://doi.org/10.1111/j.1468-3083.2004.00365.x DOI: https://doi.org/10.1111/j.1468-3083.2004.00365.x
Ikeda H, Hatamochi A, Okita H, Yamazaki S. Cardio-facio-cutaneous syndrome: two cases in the same generation. J Dermatol 2005; 32: 909-913.
https://doi.org/10.1111/j.1346-8138.2005.tb00870.x DOI: https://doi.org/10.1111/j.1346-8138.2005.tb00870.x
Modi R, Patil P, Kothiwale VA, Kamate M. Cardiofaciocutaneous syndrome. J Scientific Soc 2014; 41: 195-196.
https://doi.org/10.4103/0974-5009.141231 DOI: https://doi.org/10.4103/0974-5009.141231
Bessis D, Morice-Picard F, Bourrat E, Abadie C, Aouinti S, Baumann C. Dermatological manifestations in cardiofaciocutaneous syndrome: a prospective multicentric study of 45 mutation-positive patients. Br J Dermatol 2019; 180: 172-180.
https://doi.org/10.1111/bjd.17077 DOI: https://doi.org/10.1111/bjd.17077
Dekkers C, van der Wal MM, van den Noort L, Bakker DS, de Bruin-Weller M, van Wijk F. IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Clin Exp Allergy 2023; 53: 1222-1225.
https://doi.org/10.1111/cea.14384 DOI: https://doi.org/10.1111/cea.14384
Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol 2021; 48: 130-139.
https://doi.org/10.1111/1346-8138.15664 DOI: https://doi.org/10.1111/1346-8138.15664
Rossi M, Bettolini L, Artelli GL, Fraghì A, Tomasi C, Calzavara-Pinton P. Dupilumab treatment efficacy and impact on clinical scores, serum biomarkers, and itch in adult patients with atopic dermatitis: a retrospective analysis. J Asthma Allergy 2023; 16: 1233-1240.
https://doi.org/10.2147/JAA.S433515 DOI: https://doi.org/10.2147/JAA.S433515
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Sara A. Altandi, Pol A. Apoil, Juliette Mazereeuw-Hautier, Maella Severino-Freire
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
